Figures from the Editors selected issue highlights will be displayed each month in the journal image carousel on the BJCP homepage http://bpspubs.onlinelibrary.wiley.com/hub/journal/10.1111/(ISSN)1365‐2125/.
The November Issue of BJCP is a reflection of the breadth of clinical pharmacology. It includes papers on safety, optimization and repurposing of existing drugs, as well as improving drug prescribing. It also includes papers on the development of new drugs and diagnostics. We will discuss a few of these papers in these Issue Highlights but strongly advise you to take a look at this entire issue. We are positive you will find a paper or two that will interest you.
This issue also includes a much needed call‐for‐action. It is rare that clinical pharmacologists climb the barricades but these desperate times call for desperate measures. The call‐for‐action, initiated by BJCP's former Editor‐in‐Chief, Adam Cohen, discusses the need for transparency around COVID‐19 vaccine trials. This is imperative, as it will inform public trust and clinical uptake.
COVID‐19 vaccines: the importance of transparency and factbased Education
Adam F. Cohen, Joop van Gerven, Juan Garcia Burgos, Anthonius de Boer, Ron A. M. Foucher, H. Flore, Zvi Teitelbaum, Willem van Eden, Andrew Webb and Serge Cremers
DOI: 10.1111/bcp.14581
Most of us talk about drugs all day; the specific ones we work on, but also others, and because of the breadth of our work, our vocabulary covers a wide spectrum of drugs. I sometimes find myself reflecting on uncertainty in the precise meaning of words I use. Therefore, I am awfully glad to see papers such as the one from Jeff Aronson and the late Richard Green. In their paper, Jeff and Richard teach us about ‘me too’ drugs; their definition, their context and why we should probably think about them a bit more. The paper also nicely illustrates the valuable lessons that history holds for us.
Me‐too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists
Jeffrey K. Aronson and A. Richard Green
DOI: 10.1111/bcp.14327
We need to adjust medicine to respond to the needs of an ageing population. The October issue of BJCP highlighted several challenges facing medicines use in older people. Katja Just and colleagues, from Germany, expanded on this and investigated adverse drug reactions (ADRs) specific to older patients who presented at various emergency departments throughout Germany. They found differences in symptoms of ADRs between younger adults and older individuals, with dangerous drug‐associated phenomena in the older adults such as bleedings or falls. The authors rightfully concluded that physicians should consider drug‐associated origins of symptoms in older adults with an increased risk for serious health problems.
The phenotype of adverse drug effects: Do emergency visits due to adverse drug reactions look different in older people? Results from the ADRED study
Katja S. Just, Harald Dormann, Marlen Schurig, Miriam Böhme, Michael Steffens, Bettina Plank‐Kiegele, Kristin Ettrich, Thomas Seufferlein, Ingo Gräff, Svitlana Igel, Severin Schricker, Simon U. Jaeger, Matthias Schwab and Julia C. Stingl
DOI: 10.1111/bcp.14304
A most interesting drug repurposing strategy is described by Zaza Pudkaradze and colleagues from Grenoble, France. The authors aimed to identify existing drugs that could potentially be repurposed for Raynaud's Phenomenon (RP). They generated a repositioning hypothesis to find treatments for RP through adverse signature matching and hierarchical cluster analysis using the World Health Organization pharmacovigilance database. Besides identifying five drugs that were already in use for RP, they found two new ones‐ alemtuzumab and fumaric acid. The latter is particularly promising and could now be investigated for use in secondary Raynaud's Phenomenon. The strategy described by the authors seems to be a powerful tool to find drugs that could be repurposed.
Drug repurposing in Raynaud's phenomenon through adverse event signature matching in the World Health Organization pharmacovigilance database
Putkaradze Zaza, Roustit Matthieu, Cracowski Jean‐Luc and Khouri Charle
DOI: 10.1111/bcp.14322
Drug therapy is the most common form of treatment in medical practice. Medication related errors are a leading cause of harm, and a substantial portion of these errors are prescribing errors. It is therefore important to improve prescribing, which would decrease the number of medication errors and reduce subsequent harm. William Green and colleagues, from the UK, investigated if personalized, structured and video‐enhanced feedback and deliberate practice would improve the prescribing and patient safety behaviour of Foundation Year doctors (junior doctors in their first and second years of hospital training in the UK). They found, through an elegant prospective clinical study, that this feedback and practice indeed improves prescribing, and that the intervention is cost‐effective with potential to reduce avoidable harm. The intervention (simulated clinical encounters with personalised, structured and video‐enhanced feedback using a deliberate practice approach) is an important contribution to the WHO's Global Patient Safety challenge, Medication Without Harm.
Improving junior doctor medicine prescribing and patient safety: An intervention using personalised, structured, video‐enhanced feedback and deliberate practice
William Green, Muhammad Waseem Shahzad, Stephen Wood, Maria Martinez Martinez, Andrew Baines, Ahmad Navid, Robert Jay, Zara Whysall, John Sandars and Rakesh Patel
DOI: 10.1111/bcp.14325
Issue highlights. Br J Clin Pharmacol. 2020;86:2105–2106. 10.1111/bcp.14606
